AJCN Cancer Health Disparities Conference
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jequier, E.
Right arrow Articles by Felber, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jequier, E.
Right arrow Articles by Felber, J. P.
Agricola
Right arrow Articles by Jequier, E.
Right arrow Articles by Felber, J. P.

American Journal of Clinical Nutrition, Vol 55, 249S-251S, Copyright © 1992 by The American Society for Clinical Nutrition, Inc

REVIEW ARTICLES

Thermogenic effects of various beta-adrenoceptor agonists in humans: their potential usefulness in the treatment of obesity

E Jequier, R Munger and JP Felber
Institute of Physiology, University of Lausanne, Switzerland.

The thermogenic effect of various beta-agonists was studied in humans by using indirect calorimetry. Epinephrine was found to be markedly thermogenic: at infusion rates of 0.01, 0.03, and 0.1 microgram.min- 1.kg fat-free mass-1 resting energy expenditure (REE) increased by 8%, 16%, and 29%, respectively; in addition, a dose-dependent increase in heart rate was observed. Dopamine at high infusion rates also induces beta-agonist effects: at 5 and 10 micrograms.min-1.kg-1, REE increased by 6% and 15%, respectively, an effect that could be mediated by the release of endogenous norepinephrine. The phenethanolamine derivative Ro 16-8714 given per os at a single dose of 5 and 20 mg led to an increase of REE of 10% and 21%, whereas heart rate was enhanced by 8% and 49%, respectively. The new beta-adrenoreceptor agonist Ro 40-2148, given per os to six normal-weight young subjects at a single dose of 200 or 400 mg, induced no significant change in REE, whereas after 800 mg, REE was increased in all subjects (+3 to +17%, mean + 8%) without inducing tachycardia.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by The American Society for Nutrition